Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Warsaw - Delayed Quote PLN

Bioceltix S.A. (BCX.WA)

117.40
+1.40
+(1.21%)
As of 10:00:13 AM GMT+2. Market Open.
Currency in PLN All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
--
--
--
--
10.80
Cost of Revenue
1,380.51
1,038.08
699.99
853.86
478.55
Gross Profit
-1,380.51
-1,038.08
-699.99
-853.86
-467.75
Operating Expense
14,373.03
12,977
8,254.92
3,550.03
1,910.78
Operating Income
-15,753.54
-14,015.08
-8,954.92
-4,403.90
-2,378.52
Net Non Operating Interest Income Expense
112.77
244.99
-67.20
-17.37
12.73
Pretax Income
-15,590.47
-13,692.82
-8,967.48
-4,356.10
-2,365.79
Tax Provision
56.73
-5.27
-46.10
41.52
-17.04
Net Income Common Stockholders
-15,647.20
-13,687.55
-8,921.38
-4,397.62
-2,348.75
Diluted NI Available to Com Stockholders
-15,647.20
-13,687.55
-8,921.38
-4,397.62
-2,348.75
Basic EPS
-3.83
-3.49
-2.67
-1.39
-0.95
Diluted EPS
-3.83
-3.49
-2.67
-1.39
-0.95
Basic Average Shares
4,139.93
3,919.12
3,336.07
3,160.87
3,286.79
Diluted Average Shares
4,139.93
3,919.12
3,336.07
3,160.87
3,286.79
Total Operating Income as Reported
-15,724.61
-14,015.08
-8,900.28
-4,338.73
-2,447.76
Total Expenses
15,753.54
14,015.08
8,954.92
4,403.90
2,389.32
Net Income from Continuing & Discontinued Operation
-15,647.20
-13,687.55
-8,921.38
-4,397.62
-2,348.75
Normalized Income
-15,670.63
-13,687.55
-8,975.74
-4,450.40
-2,348.75
Interest Income
229.42
278.64
--
6.90
29.75
Interest Expense
116.64
33.65
31.51
22.95
17.02
Net Interest Income
112.77
244.99
-67.20
-17.37
12.73
EBIT
-15,473.83
-13,659.17
-8,935.98
-4,333.15
-2,348.77
EBITDA
-14,988.34
-13,224.37
-8,490.59
-3,956.17
-2,125.86
Reconciled Cost of Revenue
1,380.51
1,038.08
699.99
853.86
478.55
Reconciled Depreciation
485.49
434.80
445.39
376.98
89.02
Net Income from Continuing Operation Net Minority Interest
-15,647.20
-13,687.55
-8,921.38
-4,397.62
-2,348.75
Total Unusual Items Excluding Goodwill
28.93
--
54.64
65.17
--
Total Unusual Items
28.93
--
54.64
65.17
--
Normalized EBITDA
-15,017.27
-13,224.37
-8,545.23
-4,021.33
-2,125.86
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
5.50
--
0.28
12.38
--
12/31/2020 - 11/8/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ALZN Alzamend Neuro, Inc.
0.6620
-2.69%
 
ZVSA ZyVersa Therapeutics, Inc.
0.6751
-3.69%
 
XLO Xilio Therapeutics, Inc.
0.7852
-5.23%
 
MNPR Monopar Therapeutics Inc.
40.81
-4.45%
 
ADAP Adaptimmune Therapeutics plc
0.2771
+4.45%
 
BCAB BioAtla, Inc.
0.4449
+0.98%
 
CABA Cabaletta Bio, Inc.
1.3100
+3.15%
 
RNA Avidity Biosciences, Inc.
31.21
+1.18%
 
CRMD CorMedix Inc.
9.06
-0.44%
 
DNA Ginkgo Bioworks Holdings, Inc.
8.02
+2.30%